The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
- Conditions
- Hematological Malignancies
- Registration Number
- NCT01172132
- Lead Sponsor
- Assistance Publique - H么pitaux de Paris
- Brief Summary
The purpose of this study is to determine:
* Condition of intensive care unit (ICU) admission in patients with haematological malignancies.
* ICU hospital and up to one year mortality.
* Assessment of post ICU burden and health related quality at 90-d and 1 year.
- Detailed Description
1. To identify prognostic factors of short and medium term mortality, by underlining the respective weights of organ dysfunction and characteristics of underlined malignancy
2. Evaluate the health related quality of life of intensive care survivors(SF36)
3. Impact of intensive care on families burden (HADS, IES).
4. Assess clinicians' satisfaction ( intensivists, haematologists and intensive care nurses) in relation to medical decision-making.
5. Establish the relevance of antifungal treatments.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1011
- Hematological malignancies
- hospitalization in ICU
- age >= 18 years
- Patients who have already participated to TRIAL-OH
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival status at one year 1 year survival status (alive or death) at one year
- Secondary Outcome Measures
Name Time Method Survival status day 90 ICU mortality 1 week (estimated mean time until ICU discharge) survival status at ICU discharge
Hospital mortality 3 weeks (estimated mean time until Hospital discharge) survival status at hospital discharge
Health related quality of life of patients and their relatives day 90 and 1 year
Trial Locations
- Locations (1)
H么pital Saint-Louis, AP-HP
馃嚝馃嚪Paris, France